ストックスクリーナーアプリを入手
13.70
2.93%
0.39
アフターアワーズ：
13.73
0.03
+0.22%
前日終値:
$13.31
開ける：
$13.79
24時間の取引高:
3.68M
Relative Volume:
2.10
時価総額：
$43.43B
収益：
$30.27B
当期純損益:
$1.93B
株価収益率:
22.67
EPS:
0.6044
ネットキャッシュフロー:
$3.45B
1週間 パフォーマンス:
+6.04%
1か月 パフォーマンス:
+4.02%
6か月 パフォーマンス:
+0.37%
1年 パフォーマンス:
-5.78%
1日の値動き範囲:
$13.60
$13.88
1週間の範囲:
$12.92
$13.88
52週間の値動き範囲:
$12.57
$15.08
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
TAK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
13.70 | 43.43B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
ZTS
Zoetis Inc
|
172.71 | 77.92B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.57 | 43.27B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.84 | 20.21B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
153.29 | 15.52B | 2.24B | 385.90M | 440.10M | 3.73 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-03-16 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-07-19 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-10-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-11-01 | 開始されました | Cowen | Market Perform |
| 2019-08-15 | ダウングレード | Daiwa Securities | Outperform → Neutral |
すべてを表示
Takeda Pharmaceutical Co Adr (TAK) 最新ニュース
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights - Benzinga
Weekly Upgrades and Downgrades - InvestorPlace
Saudi Arabia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
USFDA gives tentative approval to Lupin’s generic formulation to treat type 2 diabetes - The Financial Express
Dr. Kevan Jacobson and Dr. Genelle Lunken Awarded $1M Pioneer Grant for Transformative Pediatric Research in Inflammatory Bowel Disease - Quantisnow
Things To Consider Before You Buy Takeda Pharmaceutical Co ADR (NYSE: TAK) - Stocks Register
Capital One Financial Corp (NYSE: COF): Overvalued In Comparison To Others? - Stocks Register
Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - MSN
Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Quantisnow
Australia Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Denmark Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Italy Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
UK Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
South Africa Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Tumble in Wednesday Trading - MSN
Earnings call: Takeda reports robust H1 growth, revises full-year guidance - Investing.com Australia
Earnings call: Takeda reports robust H1 growth, revises full-year guidance By Investing.com - Investing.com South Africa
Torm Plc (NASDAQ: TRMD): Getting A Free Pass? - Stocks Register
What Analysts Were Expecting After Checkpoint Therapeutics Inc (NASDAQ: CKPT) rose 2.03% - Stocks Register
Japan Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Thailand Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Dyne Therapeutics Inc (DYN) gets rating Reiterated from Chardan Capital Markets - Knox Daily
W & T Offshore Inc (WTI) receives a Buy rating from Stifel - Knox Daily
Takeda Pharmaceutical Co Adr (TAK) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
3.78%
大文字化:
|
ボリューム (24 時間):